Commentary|Videos|August 4, 2023

AI and Safety: Finding the Signals that Matter

How will AI best be positioned to help safety professionals best utilize their time and resources?

In this interview from DIA 2023, Greg Ball, Safety Data Scientist and Founder of ASAP Process Consulting, discusses artificial intelligence and its role to help safety scientists quickly sort through the hay, to find the needles in data signals.

Ball draws on his externsive experience as a biostatistician who has worked in various pharma companies to provide use case scenarios.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

Building Trust Into Oncology Real-World Evidence: Q&A with Saamir Pasha and Carole Berini, Ontada

October 16th, 2026

Building Trust Into Oncology Real-World Evidence: Q&A with Saamir Pasha and Carole Berini, Ontada

In this Q&A, Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to harmonize fragmented oncology data into reliable real-world evidence, how lab markers can proxy for missing functional status data, and where the biggest remaining barriers to consistent RWE generation lie.

© photon_photo - © photon_photo - stock.adobe.com

October 15th, 2026

Endpoints That Reflect What Patients Actually Value: Who Decides What Counts as Trial Success

Clinical trial endpoints define what success looks like, but patients and caregivers are rarely the ones setting that definition, and the gap between what trials measure and what patients actually value is showing up in post-approval evidence, regulatory submissions, and the design rooms where protocols are written.

© mod - © mod - stock.adobe.com

October 14th, 2026

FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations

A new white paper and public engagement process outline the FDA’s commitment to building fit-for-purpose evidentiary standards, stronger patient voice integration, and greater regulatory predictability across rare disease drug development and review.

© putilov_denis - © putilov_denis - stock.adobe.com

October 14th, 2026

Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection

Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.

What a Practical Roadmap for FDA and EMA Quality Frameworks Actually Looks Like

October 12th, 2026

What a Practical Roadmap for FDA and EMA Quality Frameworks Actually Looks Like

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, describe what operationalizing regulatory-grade quality frameworks requires—and why fit-for-purpose evidence generation is a transparency and documentation discipline, not just a data cleanliness exercise.

© Murrstock - © Murrstock - stock.adobe.com

October 8th, 2026

Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM

Real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis, because signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration.

© mod - © mod - stock.adobe.com

October 6th, 2026

FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review

A new FDA Voices post from the agency's acting chief of staff details completed milestones and upcoming priorities across complete response letter disclosure, application lifecycle transparency, new approach methodologies, labeling, and inspectional records.

© putilov_denis - © putilov_denis - stock.adobe.com

October 5th, 2026

Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?

Mixed FSP and FSO models are gaining ground as sponsors seek agility and resource flexibility, but the oversight infrastructure, audit trails, and accountability structures needed to run them well and survive regulatory inspection are consistently lagging behind the model itself.

Trending on Applied Clinical Trials Online

2026 SCRS Global Site Solutions Summit: What Should Sponsors and CROs Change About How They Contract with a Network?

2026 SCRS Global Site Solutions Summit: What's the Biggest Policy Gap Delaying Integrated, Community-Based Research Being the Norm?

2026 SCRS Global Site Solutions Summit: What's a Mistake Sponsors or CROs Make When Rolling Out New Trial Technology?

What It Actually Means to Embed AI Across the Clinical Operating Model

2026 SCRS Global Site Solutions Summit: Should the Industry Rethink What Scale Means?